Burgos-Morn E, Abad-Jimnez Z, Martnez de Maran A, Iannantuoni F, Escribano-Lpez I, Lpez-Domnech S, et al
Discontinuation rates due to GI intolerance were 3-7% across doses, comparable to tirzepatide
According to their published materials, they have served over 200,000 members
Clinicians can use this as an opportunity to explain, in understandable terms, how GLP1s control appetite and cravings, and to guide patients toward long-term success through behavioral and nutritional support
Mechanisms include a decline in the level of thyroid hormones that promotes compensatory increases in TSH secretion from the pituitary gland
A pooled analysis of the STEP 1-3 clinical trials found nausea affected roughly 44% of participants on semaglutide 2.4 mg, with most GI symptoms mild to moderate and concentrated in the first weeks of treatment